Article

Tipping the balance for the primary prevention of breast cancer.

Affiliation of author: Department of Hematology and Oncology, Geisinger Medical Center, Danville, PA.
CancerSpectrum Knowledge Environment (Impact Factor: 15.16). 11/2010; 102(22):1683-5. DOI: 10.1093/jnci/djq435
Source: PubMed
0 Followers
 · 
58 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to assess the potential value of large-needle core biopsies of normal breast tissue for immunohistochemical studies of epithelial risk assessment. A retrospective analysis was performed to determine the yield of nonatrophic terminal duct lobule units (TDLUs) in 11-gauge vacuum-assisted core biopsies of normal adjacent breast tissue which were included in routine stereotactic core biopsies of benign lesions. Fifty-one patients had a median of two normal tissue cores (range 1–7); 82% of the patients had two or more normal tissue cores; 47% had three or more normal tissue cores. Nonatrophic TDLUs were present in only 47% of patients and in 31% (42 of 137) of all cores. Patients with heterogeneous or dense normal mammographic parenchyma at the site of the biopsy were more likely to have nonatrophic TDLUs, 45% (20 of 44), than patients with fatty normal mammographic parenchyma at the biopsy site, 0% (0 of 7), p = 0.007. Seventy percent (7 of 10) of postmenopausal women on hormone replacement therapy had nonatrophic TDLUs as compared to 41% (11 of 27) of premenopausal and postmenopausal women not on hormones (p = not significant). Eleven-gauge vacuum-assisted core biopsies of normal breast tissue have a low yield of nonatrophic TDLUs suitable for histochemical studies of epithelial risk assessment.
    The Breast Journal 06/2000; 6(4):220 - 224. DOI:10.1046/j.1524-4741.2000.99043.x · 1.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Selective estrogen modulators can be used in the primary prevention of breast cancer in postmenopausal women.
    AAOHN Journal 01/2011; 59(1):48. DOI:10.3928/08910162-20101228-04 · 0.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: There is an increasing recognition that the mutations accompanying carcinogenesis may provide a window of therapeutic advantage designated synthetic lethality, an example of which is reported in this issue of the journal by Huang and colleagues (beginning on page 666). First discovered and studied in yeast, synthetic lethality has basic principles that have encouraged its development for treatment and now prevention in animal models of human cancer, especially malignancies refractory to standard approaches. The pros and cons of this approach and challenges in implementing it clinically are discussed.
    Cancer Prevention Research 05/2011; 4(5):628-32. DOI:10.1158/1940-6207.CAPR-11-0162 · 5.27 Impact Factor